← Back to Research Bulletin
Screening Trials: PSA Biomarker Dynamics & Indonesian BPJS Protocols
Structured Abstract
Background: Review of clinical evidence regarding Prostate-Specific Antigen (PSA) screening thresholds and the Indonesian national health insurance (BPJS) specialist referral protocol.
1. Clinical Interpretation of Serum PSA
Prostate-Specific Antigen (PSA) is an organ-specific, rather than disease-specific, biomarker. Elevated levels occur in response to benign prostatic hyperplasia (BPH), CPPS-associated micro-inflammation, and acute urinary tract infection [1]. Clinical interpretation by a physician is essential.
2. Recommended Screening Timelines
- Age 40+: High-risk cohorts (first-degree family history) should establish an individualized baseline [2].
- Age 45–50+: Routine consideration of prostate screening during annual medical checkups.
- Immediate Evaluation: Gross hematuria, acute urinary retention, or fever with dysuria.
3. Navigating Indonesian BPJS Referral Pathways
- Initial evaluation at assigned Faskes Tingkat 1 (Puskesmas or Klinik Pratama).
- Issuance of a formal Surat Rujukan to a secondary healthcare facility.
- Comprehensive specialist evaluation at the hospital Poliklinik Urologi.
⚕️ Institutional Disclaimer
Educational overview of Indonesian healthcare access. Never delay seeking urgent medical care based on online reviews.
Cited Literature & Clinical References
- [1]Schroder FH, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320-1328.
- [2]Carter HB, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190(2):419-426.